• No results found

University of Groningen Better prediction of drug response in diabetic kidney disease Idzerda, Nienke

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Better prediction of drug response in diabetic kidney disease Idzerda, Nienke"

Copied!
7
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Better prediction of drug response in diabetic kidney disease

Idzerda, Nienke

DOI:

10.33612/diss.113117223

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from

it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Idzerda, N. (2020). Better prediction of drug response in diabetic kidney disease: a biomarker approach to

personalize therapy. Rijksuniversiteit Groningen. https://doi.org/10.33612/diss.113117223

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Better prediction of

drug response

in diabetic kidney disease

(3)

The research described in this thesis was supported by the Innovative Medicines Initiative BEAt DKD programme. The BEAt DKD project has received funding from the IMI2 Joint Undertaking under grant agreement 115974. This joint undertaking receives support from the European Un-ion’s Horizon 2020 research and innovation programme and European Federation of Pharmaceu-tical Industries and Associations

Financial support for the publication of this thesis by the University of Groningen, Graduate School for Drug Exploration (GUIDE) and the Dutch Kidney Foundation is gratefully acknowledged ISBN (printed version): 978-94-034-2343-2

ISBN (electronic version): 978-94-034-2342-5

Cover design and layout: Lovebird design. www.lovebird-design.com Printing: Eikon +

Copyright © 2020 by Nienke Maria Amerins Idzerda. All rights reserved. No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, without prior permission of the author.

(4)

Better prediction of drug response

in diabetic kidney disease

A biomarker approach to personalize therapy

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 5 februari 2020 om 16.15 uur

door

Nienke Maria Amerins Idzerda

geboren op 24 september 1992

te Apeldoorn

Better prediction of drug response

in diabetic kidney disease

A biomarker approach to personalize therapy

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 5 februari 2020 om 16.15 uur

door

Nienke Maria Amerins Idzerda

geboren op 24 september 1992

te Apeldoorn

Better prediction of drug response

in diabetic kidney disease

A biomarker approach to personalize therapy

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 5 februari 2020 om 16.15 uur

door

Nienke Maria Amerins Idzerda

geboren op 24 september 1992

te Apeldoorn

Better prediction of drug response

in diabetic kidney disease

A biomarker approach to personalize therapy

Proefschrift

ter verkrijging van de graad van doctor aan de Rijksuniversiteit Groningen

op gezag van de

rector magnificus prof. dr. C. Wijmenga en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op woensdag 5 februari 2020 om 16.15 uur

door

Nienke Maria Amerins Idzerda

geboren op 24 september 1992

(5)

Promotores

Prof. dr. H.J. Lambers Heerspink Prof. dr. D. de Zeeuw

Copromotor

Dr. M.J. Pena

Beoordelingscommissie

Prof. dr. R.T. Gansevoort Prof. dr. D.E. Grobbee Prof. dr. G. Mayer

(6)

Table of Contents

Chapter 1: Introduction and aims of this thesis ... 7

Chapter 2: N-terminal pro-brain natriuretic peptide

(NT-proBNP) predicts the cardio-renal response

to aliskiren in patients with type 2 diabetes at

high renal and cardiovascular risk ... 23

Chapter 3: Proteinuria and cholesterol reduction are both

associated with less renal function decline in

statin treated patients; a post-hoc analysis of

the PLANET trials ... 39

Chapter 4: A novel drug response score more accurately

predicts renoprotective drug effects than

exist-ing renal risk scores ... 65

Chapter 5: Prediction and validation of the effects of

exenatide on progression of kidney disease in

type 2 diabetes ... 81

Chapter 6: Prediction of the effect of dapagliflozin on

renal and heart failure outcomes based on

short-term changes in multiple risk markers ... 99

Chapter 7: Summary and future perspectives ...121

Nederlandse samenvatting ... 130

(7)

Referenties

GERELATEERDE DOCUMENTEN

Advancing systems medicine based methods to predict drug response in diabetic kidney disease..

Advancing systems medicine based methods to predict drug response in diabetic kidney disease..

The long-term kidney protective effects of the sodium glucose co transporter 2 inhibitor dapaglifozin can be attributed in part to improvements in (renal) mitochondrial function.

[35–37] For the ARBs losartan and irbesartan as well as for the calcium antago- nist amlodipine, the PRE score predicted long-term renal and CV risk changes that were similar to

Volume overload is frequently observed in patients with type 2 dia- betes at high cardio-renal risk.[12,13] Extracellular volume restriction, by means of moderating dietary

Distribution of patients according to percentage change in proteinuria (UPCR ) and absolute change in total cholesterol (TC) from baseline to week 14; in all treatment groups (A)

We previously developed and validated a drug response score (multiple Parameter Response Efficacy [PRE] score) that translates the short-term drug effects on multiple

Predicted risk change for the composite renal outcome of ≥ 30% eGFR de- cline or ESRD (A) and for the composite renal outcome of ≥ 40% eGFR decline or ESRD (B) in the EXSCEL